<DOC>
	<DOCNO>NCT00002214</DOCNO>
	<brief_summary>To assess toxicity profile determine maximum tolerate dose ( MTD ) , possible , S-1153 administer orally 3 time daily 14 day . To investigate clinical pharmacokinetic parameter S-1153 . To assess anti-HIV activity associate S-1153 administration evaluation CD4 viral load measurement .</brief_summary>
	<brief_title>Phase I Trial S-1153 Patients With HIV Infection</brief_title>
	<detailed_description>Two separate schedule S-1153 administer study : single dose ( 2 dose levels/cohorts ) repeat dose administration 14 day ( escalation 4 dose levels/cohorts ) . All dos determine body weight . Single-dose study ( Cohort 1 ) : ( 4 patient ) low-dose po , follow standardized morning meal . ( 4 patient ) low-dose po , fast . Single-dose study ( Cohort 2 ) , administer first 3 level repeat dose study prior initiation 4th repeat dose level : ( 4 patient ) : intermediate-dose po , follow standardized morning meal . ( 4 patient ) : intermediate-dose po , fast . Following treatment S-1153 , single-dose patient ( Cohorts 1and 2 ) observe 21 day . Repeated dose ( escalation ) study : All dos administer 14 day . Three patient enter start dose S-1153 . In absence dose-limiting toxicity ( DLT ) , subsequent 3-patient cohort enter 3 escalating dos . The last patient give dose level must observe 21 day prior entry patient next dose . If 1 initial 3 patient experience DLT give level , 3 additional patient add dose ; additional toxicity occur , escalation resume . If 2 patient give dose exhibit DLT , previous dose declare maximum tolerate dose ( MTD ) 3 additional patient ( 6 total ) treat dose .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : 1 . Required patient CD4 cell count low 200 : PCP prophylaxis aerosolized pentamidine , trimethoprim/sulfamethoxazole , mepron , dapsone . Allowed : Continuation approve antiretroviral agent nonnucleoside reverse transcriptase inhibitor ( e.g. , Nevirapine ) specifically exclude prior medication , receive without complication least 4 week prior study entry . Patients must : Serologically document HIV infection . Singledose patient : CD4 cell count great 50 ( upper limit singledose cohort ) . Repeateddose patient : CD4 count 50 500 within 35 day prior entrance study . No active opportunistic infection . Prior Medication : Allowed entry onto multipledose study : Singledose portion S1153 study , provide study visit evaluation complete , eligibility criterion meet , minimum 30 day elapse Day 1 repeateddose administration . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active opportunistic infection . Concurrent Medication : Excluded : Concomitant use ( within 5 halflives prior administration least 24 hour follow cessation treatment S1153 ) highly plasmabound drug narrow therapeutic index , include limited coumadin dilantin . Prior Medication : 1 . Investigational new drug . Excluded within 30 day prior study entry : Chronic ( great 7 day ) use drug know affect extensively metabolize cytochrome P450 , include limited ketoconazole , fluconazole , itraconazole , isoniazid , rifampin , rifabutin , astemizole , terfenadine , protease inhibitor . Prior Treatment : Excluded within 3 week prior study entry : Cytotoxic chemotherapy . Interferon treatment . Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>